Annual report pursuant to Section 13 and 15(d)

RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

v3.8.0.1
RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE
12 Months Ended
Dec. 31, 2017
Research And Development Tax Rebate Receivable  
RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

NOTE 6: RESEARCH AND DEVELOPMENT TAX REBATE RECEIVABLE

 

On May 23, 2017 Atossa formed a wholly-owned subsidiary in Australia called Atossa Genetics AUS Pty Ltd. The purpose of this subsidiary is to perform research and development activities (“R&D”) including our Phase 1 and Phase 2 endoxifen clinical trials. Australia offers an R&D cash rebate of $0.435 per dollar spent on qualified R&D activities incurred in the country. For the period May 23, 2017 to December 31, 2017, the Company incurred qualified R&D expenses of approximately $824,000. For the year ended December 31, 2017, we have recorded an R&D rebate receivable of $358,277 and a corresponding offset to R&D expenses in the same amount.